Our Technology

Cancer will affect one in every three human beings

However early detection and lastest generation therapies have substantially improved the survival of patients diagnosed in recent years. In many cases, cancer is considered as a chronic disease, but relapses occur, even after efficient treatment, mostly induced by the survival of residual malignant cells.

The quantification of these cells after therapy (Minimal residual disease, MRD) is one of the most powerful tools to predict survival of cancer patients and help clinicians to decide when and how treat them. Altum takes advantage of a revolutionary technique called next generation sequencing (NGS), based on the read of the DNA itself to detect patient specific genetic markers (Single Nucleotide Variants (SNVs), DNA Insertions and deletions (Indels) or Immunoglobulin Rearrangements), and to quantify them after therapy (NGS-MRD).

We can identify one cancer cell in more than:

10000
normal cells using SNVs
100000
normal cells using Indels
1000000
normal cells using Immunoglobulin Rearrangements